Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
International Journal of Radiation Oncology*Biology*Physics · 2024-12 · 120 (5) · 1344-1352
DOI: 10.1016/j.ijrobp.2024.04.015 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-12. Verfasst von Johannes Rosenbrock und 14 weiteren Autor:innen. Beteiligte Einrichtung: German Hodgkin Study Group (GHSG); Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, Unive…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Cyclophosphamide, Dacarbazine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stiftung Deutsche Krebshilfe.
Abstract (Originalsprache)
PURPOSE: Combined modality treatment with chemotherapy followed by consolidation radiation therapy (RT) provides excellent outcomes for patients with early-stage Hodgkin lymphoma. The international standard of care for consolidation RT, involved-site/involved-node radiation therapy (ISRT/INRT), has never been evaluated in a randomized phase 3 trial against the former standard involved-field radiation therapy (IFRT). METHODS AND MATERIALS: In the multicenter phase 3 GHSG (German Hodgkin Study Group) HD17 trial, patients with early-stage unfavorable Hodgkin lymphoma were randomized between the standard Combined modality treatment group and a positron-emission tomography (PET)-guided group. In the standard group, patients received 2 cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) and 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy IFRT. In the experimental group, patients received no further therapy if postchemotherapy PET was negative and 30 Gy GHSG INRT, comparable to and therefore termed here ISRT, if PET was positive. Here, we analyze the interim PET-positive patients in a post hoc analysis, and therefore the randomized comparison of IFRT versus INRT/ISRT. RESULTS: A total of 1100 patients were randomized, of which 311 had a positive PET after chemotherapy. Kaplan-Meier estimates of 4-year progression-free survival were 96.8% (95% CI, 91.6%-98.8%) in the IFRT group and 95.4% (95% CI, 89.9%-97.9%; HR, 1.40; 95% CI, 0.44-4.42) in the ISRT group. The pattern of recurrence analyses indicated that none of the cases of disease progression or recurrence in the ISRT group would have been prevented by the use of IFRT. Acute grade 3/4 toxicities occurred in 8.5% of IFRT patients and 2.6% of ISRT patients (P = .03). CONCLUSIONS: For the first time, consolidation INRT/ISRT was randomly compared with IFRT in a phase 3 trial. Regarding progression-free survival, no advantage of IFRT could be demonstrated. In summary, our data confirm the status of INRT/ISRT as the current standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- German Hodgkin Study Group (GHSG); Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Electronic address: Johannes.Rosen…
- German Hodgkin Study Group (GHSG); Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
- German Hodgkin Study Group (GHSG); Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
- Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- German Hodgkin Study Group (GHSG); Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- German Hodgkin Study Group (GHSG); Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Förderung
- Stiftung Deutsche Krebshilfe
Zitieren
APA
Rosenbrock, J., Kaul, H., Oertel, M., Celik, E., Linde, P., Fan, J., Eichenauer, D. A., Bröckelmann, P. J., von Tresckow, B., Kobe, C., Dietlein, M., Fuchs, M., Borchmann, P., Eich, H. T., & Baues, C. (2024). Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group. International Journal of Radiation Oncology*Biology*Physics, 120(5), 1344-1352. https://doi.org/10.1016/j.ijrobp.2024.04.015
Vancouver
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, et al. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group. International Journal of Radiation Oncology*Biology*Physics. 2024;120(5):1344-1352. doi:10.1016/j.ijrobp.2024.04.015
BibTeX
@article{Rosenbrock2024,
author = {Rosenbrock, Johannes and Kaul, Helen and Oertel, Michael and Celik, Eren and Linde, Philipp and Fan, Jiaqi and Eichenauer, Dennis A and Bröckelmann, Paul J and von Tresckow, Bastian and Kobe, Carsten and Dietlein, Markus and Fuchs, Michael and Borchmann, Peter and Eich, Hans Theodor and Baues, Christian},
title = {Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {120},
number = {5},
pages = {1344--1352},
doi = {10.1016/j.ijrobp.2024.04.015}
}
EUVIMED